Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.
Baldo Scassellati Sforzolini, MD, PhD, MBA
Advertisement
Articles by Baldo Scassellati Sforzolini, MD, PhD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
The Emerging Role of Oral Peptide Therapeutics in Dermatology
2
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
3
Rese-cel Data Support Registrational Strategy Across Dermatomyositis, Systemic Sclerosis, Lupus
4
Suneel Chilukuri, MD on the Crucial Role of Barrier Repair and Tailored BPO Therapy
5